Background: Asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) is a new determinate syndrome whose exact characteristics remain unclear. Aim: The objective of this study is to find more difference between ACOS and COPD. Design: A retrospective study of ACOS and COPD in Chinese. Methods: Data from 65 patients with ACOS and 65 patients with COPD were retrospectively collected and analyzed. The basis of this study was to compare the two groups while ruling out differences in age, sex and smoking history. Results: Patients with ACOS tended to have earlier ages of onset, longer durations of symptoms, better nutritional status, higher single-breath diffusing capacity of carbon monoxide (DLCO) %predicted and airway resistance %predicted, more exacerbations in the preceding 12 months and shorter lengths of hospitalization. DLCO %predicted, airway resistance %pre-dicted, and length of hospitalization were the variables most significantly associated with the presence of ACOS in patients with COPD. ROC correlating airway resistance %predicted value and current ACOS showed an optimal cutoff of airway resistance %predicted of over 296.6. During follow-up (median: 45 months; interquartile range: 6-82 months), 16 patient deaths were recorded (3 patients with ACOS). The risk remained significantly higher in patients with COPD alone than in patients with ACOS (HR 3.932; 95% CI 1.083-19.755; P ¼ 0.046). Conclusion: Patients with ACOS were more likely to have better prognoses and lower mortality than those with COPD alone, though with greater exacerbation frequency.
Introduction
Asthma and chronic obstructive pulmonary disease (COPD) are common chronic diseases in the Chinese community. COPD is defined on the basis of irreversible chronic respiratory symptoms, exposure to risk factors such as smoking, and a postbronchodilator ratio of forced expiratory volume in 1 s (FEV1) to forced vital capacity (FVC) measured fewer than 70%. In contrast, asthma is characterized as having reversible, periodic symptoms. With treatment, the airway obstruction of some COPD patients can progress to partially reversible and possess other features clinically similar to asthma. 1 COPD also often shows prominent bronchodilator reversibility (>12% and >200 ml) 2 and is known to coexist with asthma. 1 Patients who have features of both diseases are defined as having asthma- Patients who have ACOS have more respiratory symptoms, more frequent exacerbations and a worse quality of life [8] [9] [10] than those with COPD alone, although the mortality rate is lower in ACOS. 4, 11 However, many distinctive traits of ACOS are illdefined from those of COPD alone. Therefore, the objective of this study is to identify the differences between ACOS and COPD alone by collecting and analyzing clinical and follow-up data from patients in a specialized hospital in Shanghai.
Materials and methods

Study subjects
The study retrospectively collected the data from 1013 consecutive inpatients diagnosed with COPD between January 2009 and September 2015 in the Shanghai Pulmonary Hospital and identified 89 patients diagnosed with both asthma and COPD. Of those, 19 patients lacked a long-term history of exposure to smoking or dust particles and a further 5 were lost to follow-up.
The remaining 65 patients were adopted into the study as the ACOS group. The characteristics of another 65 patients from the same period with COPD alone were comparatively analyzed as the COPD group. Written informed consent was obtained from all participating patients, and the study protocol was approved by the Ethics Committee of Shanghai Pulmonary Hospital (No. K15-194) . The study was performed in accordance with relevant guidelines and regulations.
Diagnosis of ACOS and COPD
The inclusion criteria of COPD were the measurement of a postbronchodilator FEV1/FVC <70%, and a history of exposure to risk factors for the disease (smokers with at least 10 pack years or long-term exposure to inhaled dust), in accordance with the criteria published by the Global Initiative for chronic obstructive lung disease (GOLD). 12 COPD diagnostic spirometry was performed at inclusion or during the previous 12 months. A positive bronchodilator test (capacity for improvement in FEV1 of at least 12% and 200 ml) denoted patients with ACOS, while a negative result indicated COPD alone. An exacerbation of COPD was defined as an acute event characterized by a worsening of the patient's respiratory symptoms beyond normal day-to-day variations that leads to a change in medication.
13,14
Interview questionnaire and blood samples
Informed consent was obtained from each subject during a medical visit by standardized protocol. The interview questionnaire used included questions on the following topics: general and anthropometric information (i.e. age, sex and body mass index), smoking history (pack-years smoked, where the smoking index was defined as the number of packs smoked per day multiplied by the number of years smoked); history of allergic disease (allergic rhinitis and a previous diagnosis of asthma before age 40), drug allergy history, asthma history within the patient's immediate family and clinical manifestation (e.g. onset of symptoms and course of disease). In addition, C-reactive protein (CRP) level and erythrocyte sedimentation rate (ESR) were used as markers of systemic inflammation, hemoglobin and albumin levels were used to assess patient nutrition, and eosinophil percentage, immunoglobulin E (IgE) and allergen levels were used to indicate allergic condition. Oxygen and carbon dioxide partial pressures (PO 2 and PCO 2 , respectively) were also assessed. Finally, blood glucose levels were collected as recent research has found correlation with COPD mortality. 15, 16 All data comparatively analyzed between the ACOS and COPD groups.
Lung function
The pulmonary function test was conducted for each patient during hospitalization. Data collected included FVC %predicted, FEV1 %predicted, FEV1/FVC, residual volume (RV) %predicted, the ratio of residual volume to total lung capacity (RV/TLC), DLCO %predicted and airway resistance (R) %predicted.
Survival analysis
All patients were routinely asked to sign a consent form upon admittance to the hospital, authorizing follow-up every 2 months through telephone or face-to-face interviews. Followup was completed on 31 October 2015. A patient was considered lost to follow up if we were unable to contact him or her for each follow-up session during the study period. The endpoint of this study was all-cause mortality. Information regarding the cause and date of death was obtained from hospital medical records for patients who died in the hospital and from official death certificates in other situations.
Statistics
The statistical package SPSS, version 19.0 (SPSS, Chicago, IL, USA), was used for statistical analysis in this study. Those variables that presented statistically significant differences (P < 0.05) in the bivariate analysis and were of clinical interest were included as the independent variables. The dependent variables were COPD and all-cause mortality. Survival curves for the two main groups (ACOS patients and those with COPD alone) were constructed according to the Kaplan-Meier method and compared using the log-rank test. For the variables we calculated sensitivity, specificity, critical point of presence of ACOS in COPD, we performed the receiving operating characteristics (ROC) curve. Hazard ratio (HR) and 95% confidence interval (CI) for the independent variables were also calculated.
Results
The differential characteristics of patients with ACOS and those with COPD alone were shown in Table 1 , there were no significant differences between them in age, sex ratio or smoking history. Patients with ACOS presented more histories of asthma in early childhood, allergic rhinitis as a comorbidity, histories of drug allergy and family histories of asthma than COPD group. Patients with ACOS tended to have earlier ages of onset, longer durations of symptoms, better nutritional status, greater allergy condition and lower systemic inflammation. Overall, they presented higher DLCO %predicted and R %predicted, a lower ratio of FEV1/FVC, lower mortality, more exacerbations in the preceding 12 months, and shorter lengths of hospitalization. DLCO %predicted (HR 1.034; 95% CI 1.015-1.054; P ¼ 0.001), R %predicted (HR 1.004; 95% CI 1.001-1.007; P ¼ 0.003) and length of hospitalization (HR 1.420; 95% CI 1.034-1.948; P ¼ 0.030) were independently associated with the presence of ACOS (Table 2) . ROC correlating R, %predicted value and current ACOS was performed in Figure 1 , showing an optimal cutoff of R, %predicted of over 296.6 (AUC 0.639; 95% CI [0.550-0.721]; sensitivity 0.615; specificity 0.692). Table 3 describes the differential characteristics of the group that survived to follow-up (n ¼ 114) and the group of patients who died (n ¼ 16). Those who died were older and tended to have longer lengths of hospitalization, and lower RV %pre-dicted, blood concentrations of albumin, hemoglobin and IgE.
Multivariate survival analysis
Kaplan-Meier survival curves for the patients with ACOS (n ¼ 65; 3 deaths) and those with COPD alone (n ¼ 65; 13 deaths) were shown in Figure 2 , indicating a significant difference between the two groups (log-rank test, 4.65; P ¼ 0.031). Table 4 shows the risk of all-cause mortality in patients with ACOS was significantly lower than in patients with COPD alone (unadjusted: HR 5.261; 95% CI 1.191-23.238; P ¼ 0.028), and remained so in the fully adjusted model (HR 3.932; 95% CI 1.083-19.755; P ¼ 0.046). Age and length of hospitalization also had independent adverse prognostic values in the fully adjusted model.
Discussion
The basis of this study was to compare patients with ACOS and those with COPD alone while ruling out differences in age, sex and smoking history. In doing so, we found that patients with ACOS were more likely to have histories of allergic disease (asthma, allergic rhinitis and drug allergy) and family histories of asthma. Previous studies have reported that ACOS patients tend to suffer from asthma and allergic rhinitis from early childhood, 17, 18 but this was the first study to report patient drug allergies and their family histories of asthma. We concluded that allergic condition was an important distinction in differentiating ACOS patients from those with COPD alone. Patients with ACOS tended to have earlier ages of onset (44.8 vs. 53.9 years, P < 0.001), longer symptom durations (17.9 vs. 11.0 years, P ¼ 0.002), more exacerbations over the preceding 12 months (2.3 vs. 1.4, P ¼ 0.015), and shorter hospital stays (9.5 d vs. 11.8 d, P ¼ 0.004). Similar results were obtained in previous studies. 19, 20 These variables indicated that patients with ACOS were more likely to have better prognoses, despite being under the condition of frequent exacerbations. higher mortality was also significantly associated with a lower body mass index in patients with COPD. In addition, patients with ACOS presented lower CRP (8.7 IU/ml vs. 22.6 IU/ml, P ¼ 0.026) and higher IgE (368.8 IU/ml vs. 208.7 IU/ml, P ¼ 0.039) levels.
Regarding lung function, ACOS patients were more likely to have lower FEV1/FVC ratios (36.4% vs. 43.6%, P ¼ 0.001), with higher values of DLCO %predicted (70.7% vs. 55.9%, P ¼ 0.001) and R %predicted (342.5% vs.281.3%, P ¼ 0.029). DLCO %pre-dicted, R %predicted, and length of hospitalization were found to be independently associated with the presence of ACOS after full adjustment of all variables. Dias et al. 21 found airway obstruction to be more severe in the asthma group (FEV1/ FVC ¼ 59%, compared with 66% for COPD), and that during exacerbations, airway constriction was more prominent in patients with asthma than in those with COPD. The significantly decreased DLCO of patients with COPD compared with that of asthmatic patients may be associated with copious alveolar damage. 21, 22 Airway resistances increased during exacerbations for both asthma and COPD, and could be reduced with adequate therapy. 23 The airway resistance of patients with ACOS resulted from the superposition of asthma and COPD, and was far higher than in COPD alone. The critical point of ROC correlating R, %predicted value and ACOS was over 296.6. Empirically, it could be said that ACOS may exist in a COPD patient whose R %pre-dicted exceeds 300. However, the sensitivity and specificity were only 60%, R, %predicted was not regarded as a criterion to distinguish ACOS and COPD alone. Overall, the patients who died tended to be older and presented longer lengths of hospitalization. After fully adjusting for covariates, the risk of patients in the elder group were found to be 1.046 times more likely to die than younger patients, independent of other variables; and the risk of patients who had COPD alone were found to be 3.932 times more likely to die than those with ACOS. The latter result was similar to the findings of a previous study. 4, 11, 24 Yamauchi et al. 11 also found higher mortality to be significantly associated with older age and reported in-hospital mortality in ACOS patients and those with COPD alone as 2.3% and 9.7%, respectively. 11 The lower mortality rate of ACOS patients relative to those with COPD alone (4.6% vs. 20%, P ¼ 0.008) may be attributable to their better nutrition and therapeutic outcomes. The main limitation of our study was in our recruiting of inpatients admitted with ACOS and COPD; these patients were more likely to have severe clinical outcomes and complications than a general population of patients with either disease. In addition, several factors shown to be associated with all-cause mortality in patients with COPD, such as the modified Medical Research Council (mMRC) dyspnea scale, were not included. Parts of symptoms (i.e. cough and dyspnea) are similar in patients with COPD or ACOS, and they were not used for distinguishing the two diseases. As this study is retrospective, some patients with ACOS might be misdiagnosed or unrecognized, which contributed the relative small size of the population of this study. However, as the comparison was between the groups with the same age, sex ratio and smoking status, the results of this study still had considerable clinical value. A prospective study with a large sample size of stable ACOS and COPD only patients should be conducted in the future.
Conclusion
Our results suggested that patients with ACOS tended to be earlier ages of onset, longer durations of symptoms, better nutritional status, greater allergy condition, lower systemic inflammation, higher DLCO %predicted and R %predicted, a lower ratio of FEV1/FVC, more exacerbations in the preceding 12 months and shorter lengths of hospitalization. Patients age and hospitalization length were found to be independent risk factors of all-cause mortality in our survival analysis of patients with COPD. Patients with ACOS were also more likely to have better prognoses and lower mortality than those with COPD alone, though with greater exacerbation frequency. 
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